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Background. SOCS proteins are known to negatively regulate insulin signaling by inhibiting insulin receptor substrate-1 (IRS1).
IRS1 has been reported to be a substrate for ubiquitin-dependent proteasomal degradation. Given that SOCS proteins can function
as substrate receptor subunits of Cullin-5 E3 ubiquitin ligases, we examined whether Cullin-5 dependent ubiquitination is involved
in the regulation of basal IRS1 protein stability and signal-induced IRS1 degradation. Findings. Our results indicate that basal IRS1
stability varies between cell types. However, the Cullin-5 E3 ligase does not play a major role in mediating IRS1 ubiquitination
under basal conditions. Protein kinase C activation triggered pronounced IRS1 destabilization. However, this eﬀect was also
independent of the function of Cullin-5 E3 ubiquitin ligases. Conclusions. In conclusion, SOCS proteins do not exert a negative
regulatory eﬀect on IRS1 by functioning as substrate receptors for Cullin-5-based E3 ubiquitin ligases both under basal conditions
and when IRS1 degradation is induced by protein kinase C activation.
1. Introduction
Insulin signaling is an important cellular process which
regulates glucose uptake and utilization, lipid and protein
synthesis as well as transcriptional responses. Binding of
insulin to the insulin receptor (IR) leads to autophospho-
rylation of the tyrosine kinase domain as well as other
proteins which interact with the IR tyrosine kinase. One of
the major IR substrates is the insulin receptor substrate (IRS)
protein, which is able to dock onto the IR. There are six
IRS related proteins, including IRS1-4, Gab1, and p62dok.
Upon insulin stimulation, these proteins are phosphorylated
on tyrosine residues and subsequently act as a multisite
docking protein for src homology 2 (SH2) domain proteins,
such as p85 phosphatidylinositol 3-kinase (PI3-kinase).
Consequently, the activation of these SH2 domain pro-
teins initiates the insulin dependent signaling cascade. One
well-characterized downstream pathway is AKT-dependent
translocation and activation of glucose transporters. Another
is AKT-dependent activation of the mTOR complex 1
(mTORC1) and the downstream serine/threonine kinase p70
S6 kinase 1 (S6K1). Functionally, this pathway is implicated
in regulating transcription, autophagy, ribosome biogenesis,
and protein stability. S6K1 has also been shown to directly
phosphorylate IRS1 and consequently exerts a negative
feedback regulation on IRS1.
Another family of SH2 domain containing proteins
is the SOCS (Suppressor Of Cytokine Signaling) protein
family. These proteins have originally been implicated in the
inhibition of the cellular response to cytokine stimulation.
However, SOCS proteins are also known to play a role
in regulating the insulin signaling pathway. SOCS protein
expression in several tissues and cell lines is increased by
insulin [1], and the induced SOCS proteins in turn were
shown to negatively regulate insulin signaling [2], suggesting
that they also mediate negative feedback regulation of the
insulin signaling pathway.
There are eight members in the SOCS protein family,
SOCS1 to SOCS7 and (cytokine-inducible SH2 domain-
containing protein) CIS [3]. The sequence of all SOCS
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proteins is similar, with a variable N-terminal domain, a
central SH2 domain and a conserved C terminal SOCS
box. While the importance of the SH2 domain for the
inhibitory action of SOCS proteins is well established, it is
currently not clear to what extent and via what mechanisms
the SOCS box contributes to the activity. Interestingly, the
SOCS box of these proteins is similar to the α domain
of the pVHL protein [4]. It is well known that pVHL
associates with elongin B/C and Cullin-2, forming an E3
ubiquitin ligase complex which facilitates the ubiquitination
and subsequent degradation of hypoxia inducible factor-1α
(HIF-1α), an important mediator of cellular oxygen sensing
[5]. Indeed, SOCS proteins have been shown to bind to
elongin B/C in vitro and in vivo [6–9]. Therefore, it can
be hypothesized that SOCS proteins may also be able to
regulate important proteins in the insulin signaling pathway
at the level of their protein stability. Additional clues for the
possible function of SOCS proteins come from the finding
that, similar to pVHL, SOCS proteins contain a Cullin box,
which mediates the binding to Cullin proteins. The Cullin
box confers specificity for Cullin proteins, as shown by pVHL
binding to CUL2 and SOCS protein binding to Cullin-5
[10].
Cullins are scaﬀold proteins for the assembly of Cullin
RING domain E3 ubiquitin ligases. There are seven mam-
malian cullin proteins (Cullin-1 to Cullin-7), which bind to
adaptor proteins and substrate receptor subunits via their
N-terminus. This substrate receptor module is responsible
for recruiting E3 ligase substrates. For instance, Cullin-5 acts
as a scaﬀold protein which recruits the adaptor proteins
elongin B/C and diﬀerent substrate receptors including
SOCS proteins. Rbx2 is a RING domain-containing protein
which binds to the C-terminus of Cullin-5 and recruits
the E2 conjugating enzyme [10], to facilitate the transfer
of ubiquitin onto the substrate. Cullin E3 ligase-mediated
polyubiquitination subsequently leads to recognition and
degradation of the substrate by the 26S proteasome.
Interestingly, it has been reported that SOCS1 and
SOCS3 bind to IRS1 and promote the ubiquitination and
degradation of the IRS1 protein [11]. Therefore, the aim of
this study is to determine whether Cul5 E3 ubiqutin ligases,
utilizing SOCS proteins as adaptor proteins, are involved in
the basal and signal induced degradation of IRS1.
2. Results
2.1. Measurement of Basal IRS1 Protein Stability in Diﬀerent
Cell Lines. To measure basal rates of IRS1 protein stability,
several cell lines were treated with a proteasome inhibitor
(MG-132) and an inhibitor of protein synthesis (cyclohex-
imide). Treatment with cycloheximide for 6 hours resulted
in a marked reduction in IRS1 protein concentrations in
HEK293T, HEK293, and HeLa cells, whereas the eﬀect in
MCF7 and 3T3-L1 cells was less pronounced. Similarly,
treatment with MG-132 caused a moderate increase in IRS1
protein levels in HEK293T, HEK293, and Hela cell lines but
was without eﬀect in MCF7 and 3T3-L1 cell lines. Thus, the
IRS1 protein in HEK293T, HEK293 and Hela cells is less
stable than in MCF7 and 3T3-L1 cells (Figure 1(a)).
To address the potential involvement of Cullin E3 ligases
in regulating basal IRS1 stability, we used the Nedd8 E1
activating enzyme (NAE) inhibitor MLN4924 which inhibits
all members of the Cullin E3 ligase family [12, 13]. Cullin
E3 ligases require the modification of the cullin protein
with the ubiquitin-like protein Nedd8 for their activity.
Treatment of cells with MLN4924 is known to result in rapid
cullin deneddylation and hence Cullin E3 ligase inhibition.
The inhibitory eﬀect of MLN4924 on the Cullin E3 ligase
family was confirmed by the marked increase in the protein
concentration of p27, HIF-1α, and Nrf2, which are bona fide
substrates for Cul1, Cul2, and Cul3 E3 ligases, respectively
[14], upon treatment with MLN4924 (Figure 1(b)). As
expected, stabilization of these Cullin E3 ligase substrates was
not aﬀected by treatment with the transcription inhibitor
Actinomycin D (Figure 1(b)).
Upon treatment with MLN4924, the IRS1 protein con-
centration was observed to increase only in HEK293T cells
but not in the other cell lines. We also measured the protein
abundance of IRS1 in HEK293 cells in the presence or
absence of MLN4924 upon inhibition of protein synthesis
with cycloheximide. However, no significant diﬀerences in
the protein abundance of IRS1 was observed over the
time course, supported by densitometry measurements
(Figure 1(c)). Even in HEK293T cells, whereMLN4924 treat-
ment increased the IRS1 protein to similar levels compared to
MG-132 (Figure 1(a)), the contribution of Cullin E3 ligases
to IRS1 protein stability is likely to be only partial. Thus, in
comparison, MLN4924 increased the protein level of the well
characterized Cul1 E3 ligase substrate p27, to even higher
levels than MG-132 (Figure 1(a)).
To investigate the involvement of Cul5 in basal IRS1
degradation, we tested whether overexpression or siRNA-
mediated silencing of this Cullin homologue in HEK293 cells
aﬀects IRS1 protein expression. As shown in Figure 2(a),
IRS1 protein levels were not significantly altered upon
overexpression or knockdown of Cul5. The above results
were confirmed by using cycloheximide treatment in cells
with Cul5 knockdown. Upon inhibition of new protein
synthesis by cycloheximide, the turnover of IRS1 was very
similar in untransfected cells and in cells transfected with
control or Cul5 siRNA (Figure 2(b)), strongly suggesting that
degradation of basal IRS1 is not mediated by Cul5. Taken
together, the results suggest that Cullin E3 ligases do not
play a major role in regulating basal IRS1 protein stability
in these cells. Given that it has been reported that diﬀerent
physiological signals are able to induce IRS1 degradation, we
investigated in further experiments whether Cullin E3 ligase-
dependent ubiquitination is involved in these regulatory
mechanisms.
2.2. Eﬀect of mTOR/S6K1 and TPA on IRS1 Protein Stability.
It is well known that chronic treatment with growth
factors induces a negative feedback regulation on IRS1
via the mTOR/S6K1 pathway, leading to S6K1-dependent
phosphorylation of IRS1. We therefore tested the eﬀect of
inhibiting basal mTOR activity in the presence of serum
on IRS1 protein concentrations. As expected, upon addition
of the mTOR inhibitor rapamycin, phosphorylation of
Biochemistry Research International 3
IRS1
p27HEK293T
IRS1
p27
IRS1
p27
IRS1
HEK293
Hela
MCF7
IRS1
3T3-L1
Cycloheximide
MG-132
− − −
− −
− −−
+
+
+
−
MLN4924
α-tubulin
α-tubulin
α-tubulin
α-tubulin
α-tubulin
(a)
NRF2
p27
−−
− −
++MLN4924
Actinomycin D + +
HIF-1α
Loading
control
(b)
IRS1
0
20
40
60
80
100
Time
α-tubulin
MLN4924
Cycloheximide (hours)
− − − − + + + +
0 2 4 6 0 2 4 6
IR
S1
 p
ro
te
in
 e
xp
re
ss
io
n
 (
%
)
0 1 2 3 4 5 6 7
−MLN4924
+MLN4924
(c)
Figure 1: Measurement of basal IRS1 protein stability in diﬀerent cell lines. (a) Cells were treated for 6 hours with the following drugs prior
to cell lysis: cycloheximide (40 μM), MG-132 (20 μM), MLN4924 (3 μM). Subsequently, Western blot analysis was performed. (b) HEK293T
cells were pretreated with actinomycin D (5 μg/mL) for 25min before adding MLN4924 (3 μM) for 4 hours, as indicated. (c) HEK293 cells
were preincubated with MLN4924 (1 μM) for 2 hours before adding cycloheximide (40 μM) for the respective time points. Cell lysates were
analyzed using Western blotting.
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Figure 2: Eﬀect of Cullin-5 knockdown on basal IRS1 protein
concentrations. (a) Negative control siRNA (NC) or two diﬀerent
Cullin-5 siRNAs were transfected into HEK293 cells, followed by
transfection of Cul5-V5 after 24 hours. After further 24 hours, the
cells were lysed with detergent lysis buﬀer and analyzed by Western
blotting. (b) HEK293 cells were transfected with negative control or
the respective Cul5 siRNA. After three days, the cells were treated
with cycloheximide (40 μM) for 6 hours, lysed, and analyzed by
Western blotting.
the mTORC1 downstream target p70 S6K was completely
prevented (Figure 3(a)). Rapamycin treatment also resulted
in an increased mobility of IRS1, indicating that S6K1
contributes to the basal phosphorylation of IRS1. However
based on densitometry results from three independent
experiments, rapamycin had no eﬀect on IRS1 protein
steady-state levels. This result suggests that mTOR/S6K1
does not regulate IRS1 basal protein stability. As previously
reported, cycloheximide treatment caused a robust activation
of mTORC1 as detected by an increase in S6K activity [15].
Cycloheximide was also found to lower the mobility of
IRS1 compared to the untreated control indicating that the
phosphorylation of IRS1 was induced. Upon coincubation
of cycloheximide with rapamycin, phosphorylation of S6K
was fully inhibited and likewise the phosphorylation of IRS1
was inhibited (Figure 3(a), lane 4). The IRS1 protein steady-
state level after 6 hours of cycloheximide was decreased
to 46% compared to the control. Interestingly, inhibition
of mTOR partially prevented the decrease in IRS1 protein
(decrease to 74% compared to control). In conclusion, our
results suggest that under basal conditions in the presence of
growth factors, mTOR/S6K is not involved in regulating IRS1
protein stability. In contrast, upon activation to higher levels,
mTOR/S6K may be involved in inducing IRS1 degradation.
Phorbol ester (TPA) has been reported to negatively
regulate IRS1 protein concentrations via PKC activation.
With this in mind, we used TPA to activate PKC in
HEK293T cells. As expected, IRS1 protein concentrations
markedly decreased upon addition of TPA, and this eﬀect
was reversed in the presence of the PKC inhibitor Go¨8963
(Figure 3(b)). Downregulation of IRS1 protein by TPA was
prevented in the presence of the proteasome inhibitor MG-
132 (see Figure 4(a)), indicating that PKC activation induces
IRS1 degradation. To confirm that the TPA-induced IRS1
downregulation is due to an eﬀect on protein stability,
a cycloheximide chase experiment was conducted in the
presence or absence of TPA. As shown in Figure 3(c), the
degradation rate of IRS1 under TPA treatment is faster than
in the control.
We also investigated the eﬀect of TPA on transfected
IRS1. Unlike the TPA-induced degradation of endogenous
IRS1, we observed that transfected IRS1 protein showed
a consistent increase in abundance upon treatment with
TPA (Figure 3(d)). To determine whether this eﬀect was
due to a nonspecific eﬀect of TPA on the CMV promoter
of the transfected plasmid, experiments were performed to
determine the eﬀect of TPA on endogenous and transfected
β-catenin expression. As expected, the endogenous β-catenin
protein levels remained unchanged upon treatment with
TPA (Figure 3(e)). When β-catenin expression plasmids with
either a CMV or a EF2 promoter were transfected into cells,
a marked upregulation of transfected β-catenin was observed
with both promoters (Figure 3(f)), albeit the CMV promoter
showed a greater eﬀect compared to the EF2 promoter. This
confirmed that TPA has a nonspecific eﬀect on the promoters
of plasmids and therefore, in subsequent experiments we
only studied the eﬀects of TPA on endogenous IRS1 protein.
2.3. Cul5 Is Not Involved in TPA-Induced IRS1 Degradation.
To determine whether the TPA-induced decrease in endoge-
nous IRS1 is due to Cullin-dependent proteasomal degrada-
tion, the NAE inhibitor MLN4924 was added to TPA treated
cells. As shown in Figure 4(a), the proteasome inhibitor MG-
132 prevented the degradation of IRS1 almost completely,
whereas MLN4924 (lane 5) only partially rescued the IRS1
protein expression. Therefore, these results show that TPA-
induced IRS1 degradation is only partially dependent on
Cullin E3 ligases.
Given the suggested role of SOCS proteins acting as
Cul5 substrate receptors in regulating IRS1 stability, we
sought to determine the role of the Cul5-based Cullin
E3 ligase in TPA-induced IRS1 degradation. To this end,
control and Cul5 siRNA duplexes were transfected into
cells and 2 days after transfection, TPA was added for
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Figure 3: Eﬀect of mTOR/S6K1 and TPA on IRS1 protein stability. (a) HEK293T cells were treated with rapamycin (20 nM) and
cycloheximide (40 μM), as indicated, for 6 h followed by cell lysis and Western blot analysis. IRS1 protein abundance was determined by
densitometry analysis indicated above the band as fold compared to the untreated control. All forms of IRS1 (shifted and not shifted) were
included in the densitometry analysis. (b) HEK293T cells were preincubated with Go¨8963 (5 nM) for one hour before 24 hour incubation
with TPA (10 nM), as indicated. (c) HEK293 cells were pretreated with 10 nM TPA for 1 hour before cycloheximide chase was conducted
using the indicated time points. Immunoblot analysis of lysates was then carried out. (d) HEK293T cells were transfected with the specified
amounts of IRS1. After the cells reached subconfluence, TPA (10 nM) was added to the medium for 24 hours before cell lysis. (e) HEK293
cells were treated with TPA (10 nM) for 24 hours followed byWestern blot analysis of cell lysates for endogenous β-catenin. (f) HEK293 cells
were transfected with 0.5 μg of the indicated β-catenin plasmids. After two days, TPA (10 nM) was added for 24 hours followed by Western
blot analysis of cell lysates with the indicated antibodies.
24 hours. Consistent with results shown above, West-
ern blot analysis revealed that basal IRS1 protein levels
remained unchanged upon Cul5 siRNA-mediated silencing
(Figure 4(b)). Importantly, Cul5 knockdown was without
eﬀect on the TPA-induced degradation of IRS1, despite
a marked reduction in Cul5 protein levels. Furthermore,
TPA treatment did not have an eﬀect on IRS2 protein
levels.
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Figure 4: Role of the Cullin-5 E3 ligase in TPA-induced IRS1 degradation. (a) HEK293 cells were treated TPA (10 nM) for the last 24 hours,
with MLN4924 (3 μM) (24 hours) and MG-132 (20 μM) (6 hours), as indicated. (b) HEK293 cells were transfected with negative control
or Cullin-5 siRNA. After two days, TPA (10 nM) was added for 24 hours. Subsequently, the cells were lysed for Western blot analysis. (c)
HEK293T cells were transfected with the respective amounts of SOCS plasmid as indicated. Immunoblot analysis of lysates was subsequently
carried out.
Finally, to directly test whether SOCS proteins are
able to promote the degradation of IRS1, overexpression
plasmids for SOCS1, SOCS3, and SOCS6, which have been
implicated in inhibiting IRS1 [11], were generated and
expressed in HEK293T cells. As shown in Figure 4(c), robust
overexpression levels of SOCS1, SOCS3, and SOCS6 did not
induce the degradation of IRS1 protein. Coexpression of
human insulin receptor and SOCS proteins in both HEK293
and HEK293T cells was also without significant eﬀect on
IRS1 protein levels (data not shown). In conclusion, our data
suggest that SOCS proteins do not exert a negative regulatory
eﬀect on IRS1 by functioning as substrate receptors for the
Cul5-based Cullin E3 ligase, both under basal conditions and
when IRS1 degradation is induced by treatment with TPA.
2.4. Discussion. SOCS proteins have been shown to nega-
tively regulate insulin signalling by inhibiting IRS1. The IRS1
protein has been reported to be a substrate for ubiquitin-
dependent proteasomal degradation [16, 17]. When mea-
suring basal protein turnover rates of IRS1 in diﬀerent
cell lines, we found that the protein was more unstable in
HEK293, HEK293T, and HeLa cells compared to MCF7 and
3T3-L1 cells. The diﬀerent basal degradation rates may be
due to diﬀerences in posttranslational modifications in the
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IRS1 protein that are important to induce its ubiquitination
and degradation or due to diﬀerences in the expression
levels or activities of E3 ubiquitin ligases involved in IRS1
ubiquitination. SOCS1 and SOCS3 have been reported to
induce IRS1 degradation [11]. Given that SOCS proteins
can function as substrate receptor subunits for Cullin-5 E3
ubiquitin ligases, it is possible that they function to recruit
IRS1 for ubiquitination. However, our results using Cullin-
5 knockdown and overexpression of SOCS proteins argue
against this possibility. Because the original study by Rui
et al. [11] used a cellular system where insulin receptor was
overexpressed, we also measured the IRS1 protein stability
in cells transfected with a human insulin receptor plasmid.
However, overexpression of insulin receptor alone or with
various SOCS proteins did not significantly aﬀect IRS1
degradation. Therefore, it is likely that other cullin and
non-cullin based E3 ligases exist which can mediate basal
IRS1 protein turnover. However, we cannot rule out that
there are cell-type specific IRS1 ubiquitination mechanisms
that involve Cullin-5 or other Cullin-based E3 ubiquitin
ligases.
The phosphorylation of IRS1 is likely to be important
for the regulation of its protein stability. For instance,
mTOR/S6K exerts a negative feedback on insulin signalling
via IRS1 phosphorylation. This negative feedback could be
due to inhibition of IRS1 activity and/or induction of IRS1
degradation. Our results suggest that mTOR/S6K might not
be involved IRS1 degradation under basal conditions in the
presence of serum. However when increased mTOR/S6K sig-
nalling occurs, for example, in the presence of cycloheximide,
IRS1 protein becomes more unstable.
The phorbol ester TPA is a well known activator of
protein kinase C α (PKCα) [18]. PKCα phosphorylates a
wide range of substrates, including IRS proteins. It has been
reported that PKCα-mediated phosphorylation causes inhi-
bition of IRS1 activity [19]. In our studies we found that TPA
decreased the IRS1 protein half-life. Furthermore, the PKC
inhibitor Go¨8963 was able to restore the IRS1 protein level in
the presence of TPA. In order to characterize the molecular
basis of TPA-induced IRS1 protein degradation, that is, to
identify involved phosphorylation sites and IRS1 ubiquitin
modification, we intended to use transfected versions of
IRS1. However, our experimental results indicated that the
transfected IRS1 protein was consistently upregulated upon
treatment with TPA, and this eﬀect is likely due to a
nonspecific eﬀect of TPA on the promoter of the transfected
plasmid.
Since TPA induced a robust degradation of the endoge-
nous IRS1 protein, the role of Cul5 mediated ubiquitination
was determined using NAE inhibitor MLN4924 and siRNA-
mediated gene silencing. Cul5 knockdown did not restore
IRS1 protein levels in the presence of TPA, suggesting that
Cullin-5 might not be the Cullin E3 ligase responsible
for the degradation of IRS1. We observed that MLN4924
partially inhibited TPA-induced IRS1 degradation. However,
it appears unlikely that TPA induces IRS1 degradation via
more than one cellular E3 ubiquitin ligase. Therefore, the
observed eﬀect of MLN4924 may be due to inhibition of
basal IRS1 protein turnover, while TPA induced degradation
is likely mediated via a diﬀerent, non-cullin based cellular E3
ubiquitin ligase.
In conclusion, our results indicate that the inhibition of
IRS1 by SOCS proteins is not primarily mediated via their
function as substrate receptor subunits of Cullin-5 based E3
ubiquitin ligases. Thus, other non-Cullin-5 based cellular
E3 ligases are likely to be responsible for basal and signal
induced IRS1 protein degradation.
3. Materials and Methods
3.1. Cell Culture. HEK293, HEK293T, HeLa, and 3T3-L1
cells were grown in DMEM medium and MCF7 cells in
RPMI medium. All media were supplemented with penicil-
lium/streptomycin, 10% fetal bovine serum (FBS), and L-
glutamine.
3.2. Immunoblotting. Cells were washed with ice-cold 1X
PBS and lysed in lysis buﬀer with 0.1% β-mercaptoethanol.
Lysates were precleared using centrifugation and equal
amounts of proteins were loaded using the Bradford protein
assay. The following antibodies were used: monoclonal anti-
glyceraldehyde-3-phosphate dehydrogenase (G8140-04; U.S.
Biological), monoclonal anti-tubulin (236-10501; Molecular
Probes), monoclonal anti-myc (2276; Cell Signaling), poly-
clonal anti-IRS1 (sc-7200; Santa Cruz Biotechnology), poly-
clonal anti-IRS2 (06-506; Upstate), monoclonal anti-p27
(610241; BD Biosciences), polyclonal anti-Nrf2 (sc722; Santa
Cruz Biotechnology), monoclonal anti-V5 (Serotec), poly-
clonal anti-p70 S6 Kinase (9202; Cell Signaling), monoclonal
anti-phospho-p70 S6 Kinase (Thr389) (9234; Cell Signaling),
monoclonal anti-HIF-1α (610959; BD Pharmingen), and
polyclonal anti-Cul5 (sc-13014; Santa Cruz Biotechnology).
Western blots shown are representative of at least two
independent experiments.
3.3. siRNA-Mediated Gene Silencing. siRNA transfection was
carried out using RNAi Max lipofectamine (Invitrogen)
according to the manufacturer’s instruction. Cells were lysed
three days after siRNA knockdown for Western blot analysis,
as described above. Cullin-5 siRNAs were obtained from
Integrated DNA Technologies (HSC.RNAI.N3478.10.3 and
HSC.RNAI.N3478.10.4).
3.4. Plasmid Constructs and Transfection of Cells. The plas-
mids pcDNA3.1-Myc-his-mIRS1 and pcDNA3.1-Myc-his-
mIRS2 were generated as previously reported [19]. To
generate the β-catenin plasmids, β-catenin coding sequence
including a C-terminal V5 tag, was inserted into KpnI
and XbaI sites of two vectors, pcDNA3 and pEF1. The
human SOCS3 and SOCS6 cDNA clone was purchased
from Geneservice (I.M.A.G.E ID 30333577 and 3917519).
To generate C-terminally FLAG tagged SOCS3 and SOCS6,
clones was PCR amplified and inserted into pcDNA3. The
human SOCS1 was PCR amplified from cDNA and inserted
into modified pcDNA3.1 with N-terminal FLAG tag. Sub-
confluent cells were transfected using Genejuice (Novagen)
according to the manufacturer’s instructions.
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